{
    "clinical_study": {
        "@rank": "9736", 
        "arm_group": {
            "arm_group_label": "Volasertib", 
            "arm_group_type": "Experimental", 
            "description": "Patient to receive escalating dose of volasertib"
        }, 
        "brief_summary": {
            "textblock": "To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese\n      patients with AML"
        }, 
        "brief_title": "Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Leukemia, Myeloid, Acute", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Patients with diagnosis of AML (except for acute promyelocytic leukemia, APL)\n             according to the World Health Organization definition and with one of the following\n             features at screening\n\n               -  Relapsed or refractory AML\n\n               -  Untreated AML patients not considered to be suitable for standard induction\n                  therapy according to investigator's judgement\n\n          2. Male or female patients of age >/= 18 years at the time of informed consent\n\n          3. Eastern Cooperative Oncology Group performance status score 0 - 2 at screening\n\n          4. Signed written informed consent consistent with Japanese Good Clinical Practice.\n\n        Exclusion criteria:\n\n          1. Patients with APL\n\n          2. Patients in the third or later relapse\n\n          3. Prior stem cell transplantation\n\n          4. Treatment with systemic therapy for the primary disease (including an investigational\n             drug) within 14 days before the first dose of volasertib with the exception of\n             hydroxyurea, or lack of recovery from any acute toxicities or clinically significant\n             adverse events pertinent to the prior systemic therapy\n\n          5. Treatment with gemtuzumab ozogamicin within 6 weeks before the first dose of\n             volasertib\n\n          6. Concomitant medication/treatment with anti-leukemic chemotherapy (systemic or\n             intrathecal), radiotherapy, immunotherapy, or any investigational agent while\n             receiving study treatment\n\n          7. Other malignancy requiring treatment at the time of screening\n\n          8. Clinical central nervous system (CNS) symptoms deemed by the investigator to be\n             related to leukemic CNS involvement or requiring treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662505", 
            "org_study_id": "1230.26"
        }, 
        "intervention": {
            "arm_group_label": "Volasertib", 
            "description": "Patient to receive volasertib", 
            "intervention_name": "Volasertib", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1230.26.002 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Isehara, Kanagawa", 
                        "country": "Japan"
                    }, 
                    "name": "1230.26.003 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maebashi, Gunma,", 
                        "country": "Japan"
                    }, 
                    "name": "1230.26.005 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagasaki, Nagasaki", 
                        "country": "Japan"
                    }, 
                    "name": "1230.26.004 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-shi, Aichi", 
                        "country": "Japan"
                    }, 
                    "name": "1230.26.001 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yoshida-gun, Fukui", 
                        "country": "Japan"
                    }, 
                    "name": "1230.26.006 Boehringer Ingelheim Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Determination of the maximum tolerated dose based on the incidence of dose limiting toxicities", 
            "safety_issue": "No", 
            "time_frame": "up to 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662505"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Complete remission (CR)", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Complete remission with incomplete blood count recovery (CRi)", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "measure": "Partial remission (PR)", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}